{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T14:29:56Z","timestamp":1788791396274,"version":"build-2803163510"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T00:00:00Z","timestamp":1749168000000},"content-version":"vor","delay-in-days":6,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,5,31]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Alzheimer\u2019s Disease (ad) patients often experience clinically significant agitation, leading to distress, increased healthcare costs and earlier institutionalisation. Current treatments have limited efficacy and significant side effects. Cannabinoid-based therapies, such as the nabiximols oral spray (Sativex\u00ae; 1:1 delta-9-tetrahydrocannabinol and cannabidiol), offer potential alternatives. We aimed to explore the feasibility and safety of nabiximols as a potential treatment for agitation in ad.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The \u2018Sativex\u00ae for Agitation &amp; Aggression in Alzheimer\u2019s Dementia\u2019 (STAND) trial was a randomised, double-blind, placebo-controlled, feasibility study conducted in UK care homes. Participants with probable ad and predefined clinically significant agitation were randomised to receive placebo or nabiximols for 4\u00a0weeks on an up-titrated schedule, followed by a 4-week observation period. To be considered feasible, we prespecified the following thresholds that needed to be met: randomising 60 participants within 12\u00a0months, achieving a\u2009\u2265\u200975% follow-up rate at 4\u00a0weeks, maintaining \u226580% adherence to allocation and estimating a minimum effect size (Cohen\u2019s d\u2009\u2265\u20090.3) on the Cohen\u2013Mansfield Agitation Inventory. This trial is registered with ISRCTN 7163562.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Findings<\/jats:title>\n                    <jats:p>Between October 2021 and June 2022, 53 candidates were assessed; 29 met eligibility criteria and were randomised. No participants withdrew, and adherence was high (100%) and was generally feasible to deliver. The intervention was well tolerated (0 adverse reactions), with no safety concerns reported.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interpretation<\/jats:title>\n                    <jats:p>Despite significant COVID-19 pandemic related challenges, administering nabiximols through oral mucosa to advanced ad patients with agitation demonstrated feasibility and safety. These findings support a larger confirmatory efficacy trial to evaluate the potential therapeutic efficacy of nabiximols for agitation in ad.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ageing\/afaf149","type":"journal-article","created":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T08:54:37Z","timestamp":1747817677000},"source":"Crossref","is-referenced-by-count":9,"title":["Sativex (nabiximols) for the treatment of Agitation &amp; Aggression in Alzheimer\u2019s dementia in UK nursing homes: a randomised, double-blind, placebo-controlled feasibility trial"],"prefix":"10.1093","volume":"54","author":[{"given":"Christopher P","family":"Albertyn","sequence":"first","affiliation":[{"name":"Centre for Healthy Brain Ageing, Department of Psychological Medicine, King\u2019s College London Institute of Psychiatry, Psychology & Neuroscience , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ta-Wei","family":"Guu","sequence":"additional","affiliation":[{"name":"Centre for Healthy Brain Ageing, Department of Psychological Medicine, King\u2019s College London Institute of Psychiatry, Psychology & Neuroscience , London ,","place":["UK"]},{"name":"Division of Psychiatry, Department of Internal Medicine, China Medical University Beigang Hospital , Beigang ,","place":["Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petrina","family":"Chu","sequence":"additional","affiliation":[{"name":"Department of Biostatistics and Health Informatics, King\u2019s College London Institute of Psychiatry Psychology & Neuroscience , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byron","family":"Creese","sequence":"additional","affiliation":[{"name":"Department of Life Sciences, Brunel University London , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allan","family":"Young","sequence":"additional","affiliation":[{"name":"School of Academic Psychiatry, King\u2019s College London Institute of Psychiatry Psychology & Neuroscience , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7712-930X","authenticated-orcid":false,"given":"Latha","family":"Velayudhan","sequence":"additional","affiliation":[{"name":"Centre for Healthy Brain Ageing, Department of Psychological Medicine, King\u2019s College London Institute of Psychiatry, Psychology & Neuroscience , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sagnik","family":"Bhattacharyya","sequence":"additional","affiliation":[{"name":"School of Academic Psychiatry, King\u2019s College London Institute of Psychiatry Psychology & Neuroscience , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hassan","family":"Jafari","sequence":"additional","affiliation":[{"name":"Department of Biostatistics and Health Informatics, King\u2019s College London Institute of Psychiatry Psychology & Neuroscience , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simrat","family":"Kaur","sequence":"additional","affiliation":[{"name":"Centre for Healthy Brain Ageing, Department of Psychological Medicine, King\u2019s College London Institute of Psychiatry, Psychology & Neuroscience , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pooja","family":"Kandangwa","sequence":"additional","affiliation":[{"name":"Centre for Healthy Brain Ageing, Department of Psychological Medicine, King\u2019s College London Institute of Psychiatry, Psychology & Neuroscience , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0318-8865","authenticated-orcid":false,"given":"Ben","family":"Carter","sequence":"additional","affiliation":[{"name":"Biostatistics and Health Informatics De Crespigny Park Denmark Hill, King\u2019s College London , London SE5 8AF ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dag","family":"Aarsland","sequence":"additional","affiliation":[{"name":"Division of Academic Psychiatry - Old Age Psychiatry, Institute of Psychiatry Psychology and Neuroscience , London ,","place":["UK"]},{"name":"Centre for Age-Related Medicine, Stavanger University Hospital , Stavanger, Rogaland ,","place":["Norway"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,6,6]]},"reference":[{"key":"2025070304265003300_ref1","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/S0140-6736(24)01296-0","article-title":"Dementia prevention, intervention, and care: 2024 report of the lancet standing commission","volume":"404","author":"Livingston","year":"2024","journal-title":"Lancet"},{"key":"2025070304265003300_ref2","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.832199","article-title":"Neuropsychiatric or behavioral and psychological symptoms of dementia (BPSD): focus on prevalence and natural history in Alzheimer\u2019s disease and frontotemporal dementia","volume":"13","author":"Lagan\u00e0","year":"2022","journal-title":"Front Neurol"},{"key":"2025070304265003300_ref3","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1017\/S104161022200103X","article-title":"Reduction and prevention of agitation in persons with neurocognitive disorders: an international psychogeriatric association consensus algorithm","volume":"36","author":"Cummings","year":"2024","journal-title":"Int Psychogeriatr"},{"key":"2025070304265003300_ref4","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1017\/S1041610222001041","article-title":"Agitation in cognitive disorders: progress in the international psychogeriatric association consensus clinical and research definition","volume":"36","author":"Sano","year":"2024","journal-title":"Int Psychogeriatr"},{"key":"2025070304265003300_ref5","doi-asserted-by":"publisher","first-page":"22","DOI":"10.7748\/nop.2023.e1435","article-title":"Dementia in care homes: increasing the diagnosis rate among undiagnosed residents","volume":"35","author":"Aldridge","year":"2024","journal-title":"Nurs Older People"},{"key":"2025070304265003300_ref6","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s40266-022-00992-5","article-title":"Implications of adverse outcomes associated with antipsychotics in older patients with dementia: a 2011\u20132022 update","volume":"40","author":"Rogowska","year":"2023","journal-title":"Drugs Aging"},{"key":"2025070304265003300_ref7","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1001\/jamaneurol.2024.0586","article-title":"Progress in pharmacologic management of neuropsychiatric syndromes in neurodegenerative disorders: a review","volume":"81","author":"Cummings","year":"2024","journal-title":"JAMA Neurol"},{"key":"2025070304265003300_ref8","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1055\/a-2262-7837","article-title":"Cannabinoids for behavioral symptoms in dementia: an overview","volume":"57","author":"Broers","year":"2024","journal-title":"Pharmacopsychiatry"},{"key":"2025070304265003300_ref9","doi-asserted-by":"publisher","first-page":"9472","DOI":"10.3390\/ijms22179472","article-title":"The endocannabinoid system: a potential target for the treatment of various diseases","volume":"22","author":"Lowe","year":"2021","journal-title":"Int J Mol Sci"},{"key":"2025070304265003300_ref10","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.3233\/JAD-141635","article-title":"The role of endocannabinoid signaling in the molecular mechanisms of neurodegeneration in Alzheimer\u2019s disease","volume":"43","author":"Bedse","year":"2015","journal-title":"J Alzheimers Dis"},{"key":"2025070304265003300_ref11","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.762738","article-title":"Reviewing the role of the endocannabinoid system in the pathophysiology of depression","volume":"12","author":"Gallego-Landin","year":"2021","journal-title":"Front Pharmacol"},{"key":"2025070304265003300_ref12","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1186\/s12916-022-02459-1","article-title":"Medical cannabinoids: a pharmacology-based systematic review and meta-analysis for all relevant medical indications","volume":"20","author":"Bilbao","year":"2022","journal-title":"BMC Med"},{"key":"2025070304265003300_ref13","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1055\/a-2256-0098","article-title":"Cannabinoids in the treatment of selected mental illnesses: practical approach and overview of the literature","volume":"57","author":"M\u00fcller-Vahl","year":"2024","journal-title":"Pharmacopsychiatry"},{"key":"2025070304265003300_ref14","doi-asserted-by":"publisher","DOI":"10.12688\/healthopenres.13311.1","article-title":"Sativex\u00ae for the treatment of Agitation & Aggression in Alzheimer\u2019s Dementia in UK nursing homes (STAND): Protocol for a feasibility randomised controlled trial [version 1; peer review: 2 approved with reservations]","volume":"5","author":"","journal-title":"Health Open Res"},{"key":"2025070304265003300_ref15","unstructured":". Study materials, SPIRIT checklist and full Statistical Analysis Plan for the Sativex\u00ae for the treatment of Agitation & Aggression in Alzheimer\u2019s Dementia in UK nursing homes (\u2018STAND\u2019) trial. figshare. Journal Contribution 2023. 10.6084\/m9.figshare.23260934.v1."},{"key":"2025070304265003300_ref16","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.jamda.2020.11.022","article-title":"Front-line nursing home staff experiences during the COVID-19 pandemic","volume":"22","author":"White","year":"2021","journal-title":"J Am Med Dir Assoc"},{"key":"2025070304265003300_ref17","doi-asserted-by":"publisher","DOI":"10.1017\/S1041610220001088","article-title":"Mental health of people living with dementia in care homes during COVID-19 pandemic","volume":"32","author":"","journal-title":"Int Psychogeriatr"},{"key":"2025070304265003300_ref18","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1017\/S1041610224000516","article-title":"Cannabidiol for behavior symptoms in Alzheimer\u2019s disease (CANBiS-AD): a randomized, double-blind, placebo-controlled trial","volume":"36","author":"Velayudhan","year":"2024","journal-title":"Int Psychogeriatr"},{"key":"2025070304265003300_ref19","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1111\/ajag.13224","article-title":"Examining the use of cannabidiol and delta-9-tetrahydrocannabinol-based medicine among individuals diagnosed with dementia living within residential aged care facilities: results of a double-blind randomised crossover trial","volume":"42","author":"Timler","year":"2023","journal-title":"Australas J Ageing"},{"key":"2025070304265003300_ref20","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1001\/jamaneurol.2023.3810","article-title":"Brexpiprazole for the treatment of agitation in Alzheimer dementia","volume":"80","author":"Lee","year":"2023","journal-title":"JAMA Neurol"},{"key":"2025070304265003300_ref21","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1111\/jgs.18372","article-title":"American Geriatrics Society 2023 updated AGS beers criteria\u00ae for potentially inappropriate medication use in older adults","volume":"71","author":"American Geriatrics Society","year":"2023","journal-title":"J Am Geriatr Soc"},{"key":"2025070304265003300_ref22","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1001\/jama.2014.93","article-title":"Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial","volume":"311","author":"Porsteinsson","year":"2014","journal-title":"JAMA"},{"key":"2025070304265003300_ref23","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1016\/S0140-6736(21)01210-1","article-title":"Study of mirtazapine for agitated behaviours in dementia (SYMBAD): a randomised, double-blind, placebo-controlled trial","volume":"398","author":"Banerjee","year":"2021","journal-title":"Lancet"},{"key":"2025070304265003300_ref24","doi-asserted-by":"publisher","first-page":"103520","DOI":"10.1016\/j.jbi.2020.103520","article-title":"Monitoring behavioral symptoms of dementia using activity trackers","volume":"109","author":"Favela","year":"2020","journal-title":"J Biomed Inform"},{"key":"2025070304265003300_ref25","doi-asserted-by":"publisher","first-page":"3211","DOI":"10.1002\/alz.13772","article-title":"Wrist-worn actigraphy in agitated late-stage dementia patients: a feasibility study on digital inclusion","volume":"20","author":"Guu","year":"2024","journal-title":"Alzheimers Dement"},{"key":"2025070304265003300_ref26","volume-title":"A Target Product Profile for an Agitation Treatment for People Living with Dementia","author":"Patel","year":"2022"},{"key":"2025070304265003300_ref27","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1111\/inm.13254","article-title":"Comparative efficacy of multiple non-pharmacological interventions for behavioural and psychological symptoms of dementia: a network meta-analysis of randomised controlled trials","volume":"33","author":"Yin","year":"2024","journal-title":"Int J Ment Health Nurs"},{"key":"2025070304265003300_ref28","doi-asserted-by":"publisher","DOI":"10.1002\/gps.5712","article-title":"Light, sleep-wake rhythm, and behavioural and psychological symptoms of dementia in care home patients: revisiting the sundowning syndrome","volume":"37","author":"Guu","year":"2022","journal-title":"Int J Geriatr Psychiatry"},{"key":"2025070304265003300_ref29","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.1038\/sj.npp.1301376","article-title":"Endocannabinoid hedonic hotspot for sensory pleasure: anandamide in nucleus accumbens shell enhances \u2018liking\u2019 of a sweet reward","volume":"32","author":"Mahler","year":"2007","journal-title":"Neuropsychopharmacology"},{"key":"2025070304265003300_ref30","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1016\/j.jagp.2021.01.015","article-title":"Cannabinoids for agitation in Alzheimer\u2019s disease","volume":"29","author":"Outen","year":"2021","journal-title":"Am J Geriatr Psychiatry"}],"container-title":["Age and Ageing"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ageing\/article-pdf\/54\/6\/afaf149\/63447270\/afaf149.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ageing\/article-pdf\/54\/6\/afaf149\/63447270\/afaf149.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T04:27:04Z","timestamp":1751516824000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ageing\/article\/doi\/10.1093\/ageing\/afaf149\/8158002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,31]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,5,31]]}},"URL":"https:\/\/doi.org\/10.1093\/ageing\/afaf149","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2024.12.18.24319032","asserted-by":"object"}]},"ISSN":["0002-0729","1468-2834"],"issn-type":[{"value":"0002-0729","type":"print"},{"value":"1468-2834","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,6]]},"published":{"date-parts":[[2025,5,31]]},"article-number":"afaf149"}}